Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nifedipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 6/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifedipine SCHEMBL29349595 | 1.00 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL3968 | 1.00 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL5694031 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27076589 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27961697 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL8851397 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL3858071 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27076587 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL8851402 | 0.99 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL9759614 | 0.96 | ADORA3 (0.93) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| CN-113750069-B | Nifedipine sustained release tablet and preparation method thereof | 北京联嘉医药科技开发有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220047511-A1 | HIGH PERFORMANCE EXCIPIENT COMPRISING CO-PROCESSED MICROCRYSTALLINE CELLULOSE AND SURFACE-REACTED CALCIUM CARBONATE | OMYA INTERNATIONAL AG (CH) | 2022-02-17 | — | — | US | disclosed |
| CN-113750069-A | Nifedipine sustained release tablet and preparation method thereof | 北京联嘉医药科技开发有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| EP-1406594-B1 | CONTROLLED AGGLOMERATION | VELOXIS PHARMACEUTICALS AS (DK) | 2019-06-05 | — | — | EP | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| EP-1069918-A4 | ENHANCEMENT OF CELLULAR GALLIUM UPTAKE | UNIV OREGON HEALTH SCIENCES (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1069918-A1 | ENHANCEMENT OF CELLULAR GALLIUM UPTAKE | Oregon Health Sciences University (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-0952770-A4 | SYSTEM FOR RENDERING SUBSTANTIALLY NON-DISSOLUBLE BIO-AFFECTING AGENTS BIO-AVAILABLE | FUISZ TECHNOLOGIES LTD (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0952770-A1 | SYSTEM FOR RENDERING SUBSTANTIALLY NON-DISSOLUBLE BIO-AFFECTING AGENTS BIO-AVAILABLE | FUISZ TECHNOLOGIES LTD. (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1999051277-A1 | ENHANCEMENT OF CELLULAR GALLIUM UPTAKE | OREGON HEALTH SCIENCES UNIVERSITY (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| WO-1997008950-A1 | SYSTEM FOR RENDERING SUBSTANTIALLY NON-DISSOLUBLE BIO-AFFECTING AGENTS BIO-AVAILABLE | FUISZ TECHNOLOGIES, LTD. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5439687-A | Having homogeneous matrix containing hydroxypropyl methyl cellulose, calcium antagonist, excipients | SIEGFRIED PHARMA AG (CH) | 1995-08-08 | — | — | US | disclosed |
| US-4954346-A | Orally administrable nifedipine solution in a solid light resistant dosage form | CIBA-GEIGY CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4803081-A | CONTAINING AN NONIONIC SOLUBILIZER | AKTIEBOLAGET HASSLE (SE) | 1989-02-07 | — | — | US | disclosed |